---
layout: post
title: "Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:58:28 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-05539
original_published: 2022-03-16 00:00:00 +0000
significance: 8.00
---

# Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 16, 2022 00:00 UTC
**Document Number:** 2022-05539

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Draft Guidance for Industry." The draft guidance document is intended to assist sponsors, including industry and academic sponsors, developing Chimeric Antigen Receptor (CAR) T cell products. The draft guidance includes CAR T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and clinical study design.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/16/2022-05539/considerations-for-the-development-of-chimeric-antigen-receptor-t-cell-products-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-05539

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
